Effect of Pioglitazone Versus Metformin on Bone Health in Postmenopausal Women With Type 2 Diabetes
Status:
Completed
Trial end date:
2014-01-01
Target enrollment:
Participant gender:
Summary
The study tests whether pioglitazone (PIO)as compared to metformin (MET)affects bone health
including bone mineral density, bone turnover markers, and osteocyte biomarker in patients
with type 2 diabetes (T2DM).